Filtered By:
Drug: Victoza

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 100 results found since Jan 2013.

Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
In this study, we found that injection of Lg significantly improved the recovery of motor function, increased cerebral blood flow and ameliorated cerebral damage in a mouse model of focal cerebral cortical ischemia. Our results revealed that Lg treatment significantly reduced the levels of NLRP3, Caspase1, IL-1β and the pore-forming protein gasdermin D in microglial cells in vitro, suggesting that the neuroprotective effect of Lg may be achieved through the inhibition of pyroptosis. Furthermore, by using a specific inhibitor of NOD-like receptor protein 3 (NLRP3), we confirmed that the antipyroptotic mechanism of Lg may b...
Source: Cell Research - March 30, 2022 Category: Cytology Authors: Lan Yang Junmin Cheng Guang Shi Cong Zhang Yuanyuan Du Linyu Chen Huimin Qiao Rong Chen Xiangjian Zhang Source Type: research

Gastrointestinal Incretins-Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease-State of the Art
We describe GIP and GLP-1 as expressed in many animal and human tissues, known to be connected to inflammation and related to enormous noncardiac and cardiovascular (CV) diseases. In animals, GIP and GLP-1 improve endothelial function and lead to reduced atherosclerotic plaque macrophage infiltration and stabilize atherosclerotic lesions by directly blocking monocyte migration. Moreover, in humans, GIPR activation induces the pro-atherosclerotic factors ET-1 (endothelin-1) and OPN (osteopontin) but also has anti-atherosclerotic effects through secretion of NO (nitric oxide). Furthermore, four large clinical trials showed a...
Source: Atherosclerosis - February 25, 2022 Category: Cardiology Authors: Szymon Jonik Micha ł Marchel Marcin Grabowski Grzegorz Opolski Tomasz Mazurek Source Type: research

GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats
AbstractLiraglutide, one of the glucagon-like peptide 1 receptor (GLP-1R) agonists, has been demonstrated to protect brain damage produced by ischemic stroke. However, it remains unknown whether liraglutide attenuates early brain injury after subarachnoid hemorrhage. The present study was performed to explore the effect of liraglutide on early brain injury after subarachnoid hemorrhage in rats, and further investigate the potential mechanisms. Sprague-Dawley rats underwent subarachnoid hemorrhage (SAH) by endovascular perforation, then received subcutaneous injection with liraglutide (50 or 100 μg/kg) or vehicle after 2 a...
Source: Inflammation - January 9, 2021 Category: Allergy & Immunology Source Type: research

The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury
Diabetes is one of the most important risk factors and comorbidities of ischemic stroke. Endoplasmic reticulum stress (ERS) is considered to be the major injury mechanism of ischemic stroke with diabetes. Studies have found that incretin can inhibit ERS in ischemia-reperfusion injury of the liver and heart. We aimed to explore the effects of GLP-1/GIP double agonist DA3-CH and GLP-1 single agonist liraglutide on ERS and apoptosis in diabetic rats with cerebral ischemia-reperfusion injury.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - September 11, 2020 Category: Nutrition Authors: Bo Bai, Dongfang Li, Guofang Xue, Peng Feng, Meiqin Wang, Yudi Han, Yanan Wang, Christian H ölscher Source Type: research

The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury
Diabetes is one of the most important risk factors and comorbidities of ischemic stroke. Endoplasmic reticulum stress (ERS) is considered to be the major injury mechanism of ischemic stroke with diabetes. Studies have found that incretin can inhibit ERS in ischemia-reperfusion injury of the liver and heart. We aimed to explore the effects of GLP-1/GIP double agonist DA3-CH and GLP-1 single agonist liraglutide on ERS and apoptosis in diabetic rats with cerebral ischemia-reperfusion injury.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - September 10, 2020 Category: Nutrition Authors: Bo Bai, DongFang Li, GuoFang Xue, Peng Feng, MeiQin Wang, YuDi Han, YaNan Wang, Christian H ölscher Source Type: research

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
AbstractPurpose of ReviewResults from cardiovascular (CV) outcome trials have revealed important insights into the CV safety and efficacy of glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).Recent FindingsAmong patients with T2DM, DPP-4i have no significant effect on risk of major adverse CV events (MACE: CV death, myocardial infarction, or stroke) with mixed results regarding risk for heart failure (HF). While sitagliptin and linagliptin have neutral effects on HF risk, saxagliptin significantly increases the risk of HF. The CV safety of ...
Source: Current Cardiology Reports - August 7, 2020 Category: Cardiology Source Type: research

Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials
This article reviews CVOTs completed to date for the class of long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs; liraglutide, exenatide extended-release, albiglutide, dulaglutide, semaglutide injectable, semaglutide oral) and implications for clinical management of T2DM. All CVOTs have confirmed long-acting GLP-1RAs to be noninferior to (not worse than) placebo with regard to first occurrence of a primary outcome of three-point major adverse cardiovascular events (MACE; composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Further, a number of the studies demonstrated a ...
Source: Journal of the American Academy of Physician Assistants - July 30, 2020 Category: Primary Care Tags: Long-Acting GLP-1 Receptor Agonists Source Type: research

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043). PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - June 29, 2020 Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues —Liraglutide and Semaglutide
ConclusionInfarct-limiting and functional neuroprotective effects of liraglutide are dose-dependent. Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs.
Source: Cardiovascular Drugs and Therapy - November 12, 2019 Category: Cardiology Source Type: research

Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis
Conclusions: In conclusion, our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and cardiovascular death among patients with type 2 diabetes.
Source: Medicine - November 1, 2019 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Publication date: Available online 14 August 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurraySummaryBackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular ou...
Source: The Lancet Diabetes and Endocrinology - August 15, 2019 Category: Endocrinology Source Type: research

The GLP ‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2
In this study, we explored the molecular mechanism of Liraglutide against oxidized low‐density lipoprotein (ox‐LDL) in cultured endothelial cells. Our data show that Liraglutide treatment ameliorates ox‐LDL caused reduction of the transcriptional factor KLF2. In the sa me experiment, Liraglutide also rescues ox‐LDL induced reduction of mitogen‐activated protein kinase (MAPK) kinase extracellular signal regulated kinase 5 (ERK5) phosphorylation, and blockage of ERK5 activity by its inhibitor XMD8‐92 abolishes the protection of Liraglutide on KLF2 expression. These facts suggest that the action of Liraglutide on ...
Source: IUBMB Life - August 5, 2019 Category: Research Authors: Wen Yue, Yi Li, Dengke Ou, Qing Yang Tags: Research Communication Source Type: research